

## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Vignin 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/526,802	03/16/2000	Jagdish Parasrampuria	4600-0131.30	1577
22798	7590 06/25/20	003		
QUINE INTELLECTUAL PROPERTY LAW GROUP, P.C. P O BOX 458 ALAMEDA, CA 94501			EXAMINER	
			QAZI, SABIHA NAIM	
<b>,</b>			ART UNIT	PAPER NUMBER
			ARI UNII	PAPER NUMBER
	•		1616	73
			DATE MAILED: 06/25/2003	65

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Advisory Action	09/526,802	PARASRAMPURIA ET AL.
, and the state of	Examiner	Art Unit
	Sabiha Qazi	1616
Th MAILING DATE of this communication appe	ears on the cover sheet with the c	correspondence address
THE REPLY FILED on 6/9/03 FAILS TO PLACE THIS 7. Therefore, further action by the applicant is required to a final rejection under 37 CFR 1.113 may only be either: (condition for allowance; (2) a timely filed Notice of Appe Examination (RCE) in compliance with 37 CFR 1.114.	void abandonment of this application in the same of th	cation. A proper reply to a chiplaces the application in
PERIOD FOR RE	PLY [check either a) or b)]	•
a) The period for reply expiresmonths from the mailing b) The period for reply expires on: (1) the mailing date of this Adverse, will the statutory period for reply expire later the ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS 706.07(f).  Extensions of time may be obtained under 37 CFR 1.136(a). The data have been filed is the date for purposes of determining the period of exten 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened (b) above, if checked. Any reply received by the Office later than three more earned patent term adjustment. See 37 CFR 1.704(b).	risory Action, or (2) the date set forth in the an SIX MONTHS from the mailing date of FILED WITHIN TWO MONTHS OF THI te on which the petition under 37 CFR 1.1 sion and the corresponding amount of the listatutory period for reply originally set in	f the final rejection.  E FINAL REJECTION. See MPEP  36(a) and the appropriate extension fee fee. The appropriate extension fee under the final Office action; or (2) as set forth in
1. A Notice of Appeal was filed on Appellant' 37 CFR 1.192(a), or any extension thereof (37 CF	s Brief must be filed within the p R 1.191(d)), to avoid dismissal o	period set forth in of the appeal.
2. The proposed amendment(s) will not be entered b		
(a) they raise new issues that would require furth	er consideration and/or search (	see NOTE below):
(b) they raise the issue of new matter (see Note I		
(c) they are not deemed to place the application issues for appeal; and/or	n better form for appeal by mate	erially reducing or simplifying the
(d) they present additional claims without cancel NOTE:	ing a corresponding number of t	inally rejected claims.
3. Applicant's reply has overcome the following reject		
4. Newly proposed or amended claim(s) would canceling the non-allowable claim(s).	be allowable if submitted in a se	eparate, timely filed amendment
5.⊠ The a)⊠ affidavit, b)□ exhibit, or c)□ request fo application in condition for allowance because: Se	reconsideration has been cons <u>e Continuation Sheet</u> .	idered but does NOT place the
6. The affidavit or exhibit will NOT be considered becaraised by the Examiner in the final rejection.	ause it is not directed SOLELY	to issues which were newly
7. For purposes of Appeal, the proposed amendment explanation of how the new or amended claims we	(s) a)  will not be entered or b) puld be rejected is provided belo	will be entered and an
The status of the claim(s) is (or will be) as follows:	•	••
Claim(s) allowed:		
Claim(s) objected to:		
Claim(s) rejected: <u>1-10 and 36-39</u> .		
Claim(s) withdrawn from consideration:		
8. The proposed drawing correction filed on is	a)□ approved or b)□ disapp	roved by the Examiner.
9. Note the attached Information Disclosure Statemer		
10. Other:	50	D 20/
	SABIHA Q/ PRIMARY E	AZI, PH.D :XAMINER
U.S. Patent and Trademark Office PTO-303 (Rev. 04-01)  Advis	ory Action	Part of Paper No. 23

Continuation Sheet (PTO-303) 09/526,802

Continuation of 5. does NOT place the application in condition for allowance because: the declaration shows that form 1 has two crystallographically independent molecules in the structure, however prior art teach s that form 1 may have contamination. The pharmaceutical formulation as claimed (such as in claim 1) contains at least 85% of DHEA, the formulation of DHEA is taught by the prior art. No unexpected results are seen. No claim is allowed. Rejection is maintained for the same reasons as set forth in our previous office actions.